{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T08:48:00Z","timestamp":1745916480877,"version":"3.37.3"},"reference-count":78,"publisher":"Oxford University Press (OUP)","issue":"Supplement_G","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cardiovascular Research Institute of Vermont and the Heart Rhythm Society"},{"name":"University of Minnesota and the Engdahl Family Foundation"},{"DOI":"10.13039\/100010941","name":"University of Vermont","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010941","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent with a high socioeconomic burden. Pharmacological heart rate lowering was recommended to improve ventricular filling in HFpEF. This article discusses the misperceptions that have resulted in an overprescription of beta-blockers, which in all likelihood have untoward effects on patients with HFpEF, even if they have atrial fibrillation or coronary artery disease as a comorbidity. Directly contradicting the lower heart rate paradigm, faster heart rates provide haemodynamic and structural benefits, amongst which lower cardiac filling pressures and improved ventricular capacitance may be most important. Safe delivery of this therapeutic approach is feasible with atrial and ventricular conduction system pacing that aims to emulate or enhance cardiac excitation to maximize the haemodynamic benefits of accelerated pacing. This conceptual framework was first tested in the myPACE randomized controlled trial of patients with pre-existing pacemakers and preclinical or overt HFpEF. This article provides the background and path towards this treatment approach.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suad117","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T23:47:27Z","timestamp":1699660047000},"page":"G33-G43","source":"Crossref","is-referenced-by-count":2,"title":["Personalized accelerated physiologic pacing"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4398-5642","authenticated-orcid":false,"given":"Markus","family":"Meyer","sequence":"first","affiliation":[{"name":"Department of Medicine, Larner College of Medicine, University of Vermont , Burlington, 111 Colchester Avenue, McClure Level 1, Burlington, VT 05401, USA"},{"name":"Department of Medicine, Lillehei Heart Institute, University of Minnesota College of Medicine , 2231 6th St. SE, 4-165 CCRB, Minneapolis, MN 55455, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Infeld","sequence":"additional","affiliation":[{"name":"Department of Medicine, Larner College of Medicine, University of Vermont , Burlington, 111 Colchester Avenue, McClure Level 1, Burlington, VT 05401, USA"},{"name":"Cardiovascular Center, Tufts Medical Center and Tufts University School of Medicine , 800 Washington Street, Boston, MA 02111, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Habel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Larner College of Medicine, University of Vermont , Burlington, 111 Colchester Avenue, McClure Level 1, Burlington, VT 05401, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lustgarten","sequence":"additional","affiliation":[{"name":"Department of Medicine, Larner College of Medicine, University of Vermont , Burlington, 111 Colchester Avenue, McClure Level 1, Burlington, VT 05401, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"2023111023464371800_suad117-B1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10741-017-9660-1","article-title":"Pharmacological heart rate lowering in patients with a preserved ejection fraction\u2014review of a failing concept","volume":"23","author":"Meyer","year":"2018","journal-title":"Heart Fail Rev"},{"key":"2023111023464371800_suad117-B2","doi-asserted-by":"crossref","first-page":"e006213","DOI":"10.1161\/CIRCHEARTFAILURE.119.006213","article-title":"Heart rate and heart failure with preserved ejection fraction: time to slow \u03b2-blocker use?","volume":"12","author":"Meyer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2023111023464371800_suad117-B3","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/europace\/euad010","article-title":"Beta-blockers in atrial fibrillation-trying to make sense of unsettling results","volume":"25","author":"Meyer","year":"2023","journal-title":"Europace"},{"key":"2023111023464371800_suad117-B4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/BF01864726","article-title":"\u00dcber den Einflu\u00df der mechanischen Bedingungen auf die T\u00e4tigkeit und den Sauerstoffverbrauch des Warmbl\u00fcterherzens","volume":"68","author":"Rohde","year":"1912","journal-title":"Arch Exp Pathol Pharmakol"},{"key":"2023111023464371800_suad117-B5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(64)91075-X","article-title":"Propranolol","volume":"2","author":"Grant","year":"1964","journal-title":"Lancet"},{"key":"2023111023464371800_suad117-B6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM198501313120504","article-title":"Hypertensive hypertrophic cardiomyopathy of the elderly","volume":"312","author":"Topol","year":"1985","journal-title":"N Engl J Med"},{"key":"2023111023464371800_suad117-B7","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cardfail.2021.04.015","article-title":"Association between \u03b2-blockers and outcomes in HFpEF: current insights from the SwedeHF registry","volume":"27","author":"Meyer","year":"2021","journal-title":"J Card Fail"},{"key":"2023111023464371800_suad117-B8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023111023464371800_suad117-B9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2023111023464371800_suad117-B10","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"Beta blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"2023111023464371800_suad117-B11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"2023111023464371800_suad117-B12","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"2023111023464371800_suad117-B14","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis","volume":"384","author":"Kotecha","year":"2014","journal-title":"Lancet"},{"key":"2023111023464371800_suad117-B15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2023111023464371800_suad117-B16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"2023111023464371800_suad117-B17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"2023111023464371800_suad117-B18","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","article-title":"Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis","volume":"394","author":"Suchard","year":"2019","journal-title":"Lancet"},{"key":"2023111023464371800_suad117-B19","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B20","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1093\/eurheartj\/ehac285","article-title":"Post-operative atrial fibrillation and risk of heart failure hospitalization","volume":"43","author":"Goyal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023111023464371800_suad117-B21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jacbts.2019.05.005","article-title":"Atrial myopathy","volume":"4","author":"Shen","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"2023111023464371800_suad117-B22","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B23","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999\u20132012","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"key":"2023111023464371800_suad117-B24","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2023111023464371800_suad117-B26","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cardfail.2019.08.020","article-title":"Beta-blocker cessation in stable outpatients with heart failure with a preserved ejection fraction","volume":"26","author":"Nambiar","year":"2020","journal-title":"J Card Fail"},{"key":"2023111023464371800_suad117-B28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ahj.2006.02.033","article-title":"RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II","volume":"152","author":"Van Gelder","year":"2006","journal-title":"Am Heart J"},{"key":"2023111023464371800_suad117-B29","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B30","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"2023111023464371800_suad117-B31","doi-asserted-by":"crossref","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2023111023464371800_suad117-B32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2021.10.049","article-title":"Beta-blocker use in hypertension and heart failure (a secondary analysis of the systolic blood pressure intervention trial)","volume":"165","author":"Silverman","year":"2021","journal-title":"Am J Cardiol"},{"key":"2023111023464371800_suad117-B33","doi-asserted-by":"crossref","first-page":"200182","DOI":"10.1016\/j.ijcrp.2023.200182","article-title":"Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation","volume":"17","author":"Habel","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2023111023464371800_suad117-B34","first-page":"1104","article-title":"Rest heart rate and life expectancy","volume":"30","author":"Levine","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B35","doi-asserted-by":"crossref","first-page":"25329","DOI":"10.1073\/pnas.1914273116","article-title":"Extreme bradycardia and tachycardia in the world's largest animal","volume":"116","author":"Goldbogen","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023111023464371800_suad117-B36","first-page":"1","article-title":"Resting pulse rate reference data for children, adolescents, and adults: United States, 1999\u20132008","author":"Ostchega","year":"2011;41","journal-title":"Natl Health Stat Rep"},{"key":"2023111023464371800_suad117-B37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.hroo.2020.09.004","article-title":"An approach towards individualized lower rate settings for pacemakers","volume":"1","author":"Infeld","year":"2020","journal-title":"Heart Rhythm O2"},{"key":"2023111023464371800_suad117-B38","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.116.07250","article-title":"Selective heart rate reduction with ivabradine increases central blood pressure in stable coronary artery disease","volume":"67","author":"Rimoldi","year":"2016","journal-title":"Hypertension"},{"key":"2023111023464371800_suad117-B39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2009.02.088","article-title":"Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate","volume":"54","author":"Williams","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/CIRCIMAGING.108.819938","article-title":"Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis","volume":"2","author":"Cheng","year":"2009","journal-title":"Circ Cardiovasc Imaging"},{"key":"2023111023464371800_suad117-B41","first-page":"193","article-title":"Epidemiology of resting pulse rate of persons ages 25\u201374\u2013data from NHANES 1971\u201374","volume":"107","author":"Gillum","year":"1992","journal-title":"Public Health Rep"},{"key":"2023111023464371800_suad117-B42","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1161\/CIRCULATIONAHA.116.018011","article-title":"Sinus node and atrial arrhythmias","volume":"133","author":"John","year":"2016","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B43","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1093\/eurheartj\/ehr311","article-title":"Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy","volume":"32","author":"Tardif","year":"2011","journal-title":"Eur Heart J"},{"key":"2023111023464371800_suad117-B44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fphys.2019.00042","article-title":"Role of myokines in regulating skeletal muscle mass and function","volume":"10","author":"Lee","year":"2019","journal-title":"Front Physiol"},{"key":"2023111023464371800_suad117-B45","doi-asserted-by":"crossref","first-page":"e010395","DOI":"10.1161\/CIRCHEARTFAILURE.123.010395","article-title":"Left ventricular gene expression in heart failure with preserved ejection fraction\u2014pro-fibrotic and pro-inflammatory pathways and genes","volume":"16","author":"Ye","year":"2023;","journal-title":"Circ Heart Fail"},{"key":"2023111023464371800_suad117-B46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/01.CIR.43.2.241","article-title":"Analysis of left ventricular function by atrial pacing","volume":"43","author":"Parker","year":"1971","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B47","doi-asserted-by":"crossref","first-page":"H1203","DOI":"10.1152\/ajpheart.00681.2004","article-title":"Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure","volume":"288","author":"Hay","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2023111023464371800_suad117-B48","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/01.CIR.76.6.1232","article-title":"Effects of pacing-induced ischemia on early left ventricular filling and regional myocardial dynamics and their modification by nifedipine","volume":"76","author":"Nakamura","year":"1987","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B49","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/01.CIR.79.2.371","article-title":"Beta-adrenergic stimulation with isoproterenol enhances left ventricular diastolic performance in hypertrophic cardiomyopathy despite potentiation of myocardial ischemia. Comparison to rapid atrial pacing","volume":"79","author":"Udelson","year":"1989","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B50","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","article-title":"Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction","volume":"114","author":"Borlaug","year":"2006","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B51","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.107.716886","article-title":"Role of left ventricular stiffness in heart failure with normal ejection fraction","volume":"117","author":"Westermann","year":"2008","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B52","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1093\/eurheartj\/ehp341","article-title":"Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure","volume":"30","author":"Wachter","year":"2009","journal-title":"Eur Heart J"},{"key":"2023111023464371800_suad117-B53","doi-asserted-by":"crossref","first-page":"e017215","DOI":"10.1161\/JAHA.120.017215","article-title":"Heart rate-induced myocardial Ca2+ retention and left ventricular volume loss in patients with heart failure with preserved ejection fraction","volume":"9","author":"Silverman","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2023111023464371800_suad117-B54","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/CIRCULATIONAHA.121.056412","article-title":"A targeted treatment opportunity for HFpEF: taking advantage of diastolic tone","volume":"144","author":"Meyer","year":"2021","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B55","doi-asserted-by":"crossref","first-page":"e004311","DOI":"10.1161\/CIRCHEARTFAILURE.117.004311","article-title":"Relaxation and the role of calcium in isolated contracting myocardium from patients with hypertensive heart disease and heart failure with preserved ejection fraction","volume":"10","author":"Runte","year":"2017","journal-title":"Circ Heart Fail"},{"key":"2023111023464371800_suad117-B56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jacc.2010.10.069","article-title":"Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction","volume":"58","author":"Selby","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B57","doi-asserted-by":"crossref","first-page":"e15446","DOI":"10.14814\/phy2.15446","article-title":"Heart rate changes and myocardial sodium","volume":"10","author":"Nelson","year":"2022","journal-title":"Physiol Rep"},{"key":"2023111023464371800_suad117-B58","first-page":"H779","article-title":"Phospholamban-to-SERCA2 ratio controls the force-frequency relationship","volume":"276","author":"Meyer","year":"1999","journal-title":"Am J Physiol"},{"key":"2023111023464371800_suad117-B59","doi-asserted-by":"crossref","first-page":"H249","DOI":"10.1152\/ajpheart.2000.278.1.H249","article-title":"Phospholamban: a major determinant of the cardiac force-frequency relationship","volume":"278","author":"Bluhm","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2023111023464371800_suad117-B60","doi-asserted-by":"crossref","first-page":"H1031","DOI":"10.1152\/ajpheart.00301.2016","article-title":"Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept","volume":"311","author":"Klein","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2023111023464371800_suad117-B61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cardfail.2018.06.009","article-title":"Safety and feasibility of a nocturnal heart rate elevation-exploration of a novel treatment concept","volume":"25","author":"Yeshwant","year":"2019","journal-title":"J Card Fail"},{"key":"2023111023464371800_suad117-B62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0735-1097(21)01582-5","article-title":"Personalized pacing (myPACE): a new paradigm for diastolic heart failure treatment","volume":"77","author":"Infeld","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0735-1097(21)01582-5","article-title":"Personalized pacing (myPACE): a new paradigm for the treatment of diastolic dysfunction or HFpEF","volume":"77","author":"Margaret","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.hrthm.2009.09.066","article-title":"Electrical resynchronization induced by direct His-bundle pacing","volume":"7","author":"Lustgarten","year":"2010","journal-title":"Heart Rhythm"},{"key":"2023111023464371800_suad117-B65","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.hrthm.2021.11.015","article-title":"Bachmann bundle potential during atrial lead placement: a case series","volume":"19","author":"Infeld","year":"2021","journal-title":"Heart Rhythm"},{"key":"2023111023464371800_suad117-B66","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/01.CIR.101.3.336","article-title":"The athlete\u2019s heart. A meta-analysis of cardiac structure and function","volume":"101","author":"Pluim","year":"2000","journal-title":"Circulation"},{"key":"2023111023464371800_suad117-B67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jacc.2004.02.057","article-title":"Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up","volume":"44","author":"Abergel","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B68","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/ajh.2012.49","article-title":"Nocturnal hypertension and organ damage in dippers and nondippers","volume":"25","author":"Cuspidi","year":"2012","journal-title":"Am J Hypertens"},{"key":"2023111023464371800_suad117-B69","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jacc.2008.09.014","article-title":"The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study","volume":"52","author":"Bluemke","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2023111023464371800_suad117-B70","doi-asserted-by":"crossref","first-page":"43F","DOI":"10.1016\/0002-9149(86)90888-X","article-title":"Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials","volume":"57","author":"Kjekshus","year":"1986","journal-title":"Am J Cardiol"},{"key":"2023111023464371800_suad117-B71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.hroo.2021.11.015","article-title":"Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: design and rationale for the","volume":"3","author":"Infeld","year":"2022","journal-title":"Heart Rhythm O2"},{"key":"2023111023464371800_suad117-B72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2023111023464371800_suad117-B73","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/eurjhf\/hft139","article-title":"Meta-analysis of symptomatic response attributable to the pacing component of cardiac resynchronization therapy","volume":"15","author":"Sohaib","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2023111023464371800_suad117-B74","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jchf.2018.04.010","article-title":"A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation","volume":"6","author":"Abraham","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2023111023464371800_suad117-B75","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0140-6736(16)00704-2","article-title":"A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial","volume":"387","author":"Hasenfu\u00df","year":"2016","journal-title":"Lancet"},{"key":"2023111023464371800_suad117-B76","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1001\/jama.2023.7946","article-title":"Rate-adaptive atrial pacing for heart failure with preserved ejection fraction-reply","volume":"329","author":"Reddy","year":"2023","journal-title":"JAMA"},{"key":"2023111023464371800_suad117-B77","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ejhf.2021","article-title":"Mechanical circulatory support does not reduce advanced myocardial fibrosis in patients with end-stage heart failure","volume":"23","author":"Kassner","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2023111023464371800_suad117-B78","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad518","article-title":"Beta-blockers in non-obstructive hypertrophic cardiomyopathy: time to ease the heart rate restriction?","volume":"ehad518","author":"Weissler-Snir","year":"2023","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_G\/G33\/53134556\/suad117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/25\/Supplement_G\/G33\/53134556\/suad117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T23:48:02Z","timestamp":1699660082000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/25\/Supplement_G\/G33\/7394244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":78,"journal-issue":{"issue":"Supplement_G","published-online":{"date-parts":[[2023,11,9]]},"published-print":{"date-parts":[[2023,11,9]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suad117","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"type":"print","value":"1520-765X"},{"type":"electronic","value":"1554-2815"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11]]}}}